Nanoparticle Delivery of Novel PDE4B Inhibitor for the Treatment of Alcoholic Liver Disease
The incidence of alcoholic liver disease (ALD) is increasing worldwide while no effective treatment has been approved. The progression of ALD has proven to be related to the upregulation of phosphodiesterase 4 (PDE4) expression, and PDE4 inhibitors showed potential to improve ALD. However, the appli...
Main Authors: | Jingyi Ma, Virender Kumar, Ram I. Mahato |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/9/1894 |
Similar Items
-
PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes
by: Jian Jin, et al.
Published: (2023-07-01) -
An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022
by: Letizia Crocetti, et al.
Published: (2022-08-01) -
Inhibition of PDE‐4 isoenzyme attenuates frequency and overall contractility of agonist‐evoked ureteral phasic contractions
by: Iris Lim, et al.
Published: (2024-02-01) -
Clinical Implication of Phosphodiesterase-4-Inhibition
by: Martin Alexander Schick, et al.
Published: (2022-01-01) -
Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases
by: Vincent Lagente, et al.
Published: (2005-03-01)